XP-828L (Dermylex), a new whey protein extract with potential benefit for mild to moderate psoriasis

Canadian Journal of Physiology and Pharmacology

Volumn 85, Issue 9, 2007, Pages 943-951

  Drouin, Réjean ^a   Lamiot, Éric ^a   Cantin, Kim ^a   Gauthier, Sylvie F ^b   Pouliot, Yves ^b   Poubelle, Patrice E ^c   Juneau, Christina ^a  

^a Advitech Inc   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c LAVAL UNIVERSITY   (Canada)

Author keywords

Autoimmune diseases; Cytokines; Dermylex; Mild to moderate psoriasis; Natural health product; T lymphocyte; XP 828L

Indexed keywords

CONCANAVALIN A; DERMYLEX; GAMMA INTERFERON; INTERLEUKIN 2; PLANT EXTRACT; UNCLASSIFIED DRUG; WHEY EXTRACT; XP 828L;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; DATA ANALYSIS; DISEASE SEVERITY; DRUG MECHANISM; DRUG SAFETY; FEMALE; GENE EXPRESSION; HEMATOLOGY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; SCORING SYSTEM; SPLEEN CELL; THERAPY EFFECT;

ADULT; AGED; ANIMALS; CELL PROLIFERATION; CYTOKINES; FEMALE; HUMANS; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; MILK PROTEINS; PSORIASIS; SPLEEN;

EID: 36549069144     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/Y07-084     Document Type: Article

References (48)

1. Austin, L.M., Ozawa, M., Kikuchi, T., Walters, I.B., and Krueger, J.G. 1999. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J. Invest. Dermatol. 113: 752-759. doi:10.1046/j.1523-1747.1999.00749.x.
2. Ben-Arye, E., Ziv, M., Fenkel, M., Lavi, I., and Rosenman, D. 2003. Complementary medicine and psoriasis: Linking the patient's outlook with evidence-based medicine. Dermatology, 207: 302-307. doi:10.1159/ 000073094.
3. Bjorneboe, A., Soyland, E., Bjorneboe, G.E., Rajka, G., and Drevon, C.A. 1989. Effect of n-3 fatty acid supplement to patients with atopic dermatitis. J. Intern. Med. Suppl. 731(Suppl.): 233-236.
4. Bounous, G., and Kongshavn, P.A. 1985. Differential effect of dietary protein type on the B-cell and T-cell immune responses in mice. J. Nutr. 115: 1403-1408.
5. Bounous, G., Kongshavn, P.A., and Gold, P. 1988. The immunoenhancing property of dietary whey protein concentrate. Clin. Invest. Med. 11: 271-278.
6. Bowcock, A.M., and Krueger, J.G. 2005. Getting under the skin: the immunogenetics of psoriasis. Nat. Rev. Immunol. 5: 699-711. doi:10.1038/nri1689.
7. Chamian, F., and Krueger, J.G. 2004. Psoriasis vulgaris: an interplay of T lymphocytes, dendritic cells, and inflammatory cytokines in pathogenesis. Curr. Opin. Rheumatol. 16: 331-337. doi:10.1097/01.bor.0000129715.35024. 50.
8. Christophers, E., Griffiths, C.E., Gaitanis, G., and van de Kerkhof, P. 2006. The unmet treatment need for moderate to severe psoriasis: results of a survey and chart review. J. Eur. Acad. Dermatol. Venereol. 20: 921-925. doi:10.1111/j.1468-3083.2006.01773.x.
9. Crane, I.J., and Forrester, J.V. 2005. Th1 and Th2 lymphocytes in autoimmune disease. Crit. Rev. Immunol. 25: 75-102. doi:10.1615/ CritRevImmunol.v25.i2.10.
10. Cross, M.L., and Gill, H.S. 1999. Modulations of immune function by a modified bovine whey protein concentrate. Immunol. Cell Biol. 77: 345-350. doi:10.1046/j.1440-1711.1999.00834.x.
11. Del Prete, G. 1992. Human Th1 and Th2 lymphocytes: their role in the pathophysiology of atopy. Allergy, 47: 450-455. doi:10.1111/j.1398-9995. 1992.tb00662.x.
12. Fantini, M.C., Becker, C., Monteleone, G., Pallone, F., Galle, P.R., and Neurath, M.F. 2004. Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J. Immunol. 172: 5149-5153.
13. Finlay, A.Y., and Ortonne, J.P. 2004. Patient satisfaction with psoriasis therapies: an update and introduction to biologic therapy. J. Cutan. Med. Surg. 8: 310-320. doi:10.1007/s10227-005-0030-6.
14. Gaspari, A.A. 2006. Innate and adaptive immunity and the pathophysiology of psoriasis. J. Am. Acad. Dermatol. 54: S67-S80. doi:10.1016/j.jaad. 2005.10.057.
15. Gattegno, L., Migliore-Samour, D., Saffar, L., and Jolies, P. 1988. Enhancement of phagocytic activity of human monocyticmacrophagic cells by immunostimulating peptides from human casein. Immunol. Lett. 18: 27-31. doi:10.1016/0165-2478(88)90065-X.
16. Gauthier, S.F., Pouliot, Y., and Saint-Sauveur, D. 2006. Immunomodulatory peptides obtained by the enzymatic hydrolysis of whey proteins. Int. Dairy J. 16: 1315-1323. doi:10.1016/j.idairyj.2006.06.014.
17. Gorelik, L., and Flavell, R.A. 2002. Transforming growth factor-beta in T-cell biology. Nat. Rev. Immunol. 2: 46-53. doi:10.1038/nri704.
18. Gupta, A.K., Ellis, C.N., Tellner, D.C., Anderson, T.F., and Voorhees, J.J. 1989. Double-blind, placebo-controlled study to evaluate the efficacy of fish oil and low-dose UVB in the treatment of psoriasis. Br. J. Dermatol. 120: 801-807. doi:10.1111/j.1365-2133.1989.tb01378.x.
19. Gupta, A.K., Ellis, C.N., Goldfarb, M.T., Hamilton, T.A., and Voorhees, J.J. 1990. The role of fish oil in psoriasis. A randomized, double-blind, placebo-controlled study to evaluate the effect of fish oil and topical corticosteroid therapy in psoriasis. Int. J. Dermatol. 29: 591-595. doi:10.1111/j.1365-4362.1990.tb03477.x.
20. Hayashida, K., Kaneko, T., Takeuchi, T., Shimizu, H., Ando, K., and Harada, E. 2004. Oral administration of lactoferrin inhibits inflammation and nociception in rat adjuvant-induced arthritis. J. Vet. Med. Sci. 66: 149-154. doi:10.1292/jvms.66.149.
21. Heydendael, V.M., de Borgie, C.A., Spuls, P.I., Bossuyt, P.M., Bos, J.D., and de Rie, M.A. 2004. The burden of psoriasis is not determined by disease severity only. J. Investig. Dermatol. Symp. Proc. 9: 131-135. doi:10.1111/j.1087-0024.2004.09115.x.
22. Jaziri, M., Migliore-Samour, D., Casabianca-Pignede, M.R., Keddad, K., Morgat, J.L., and Jolies, P. 1992. Specific binding sites on human phagocytic blood cells for Gly-Leu-Phe and Val-Glu-Pro-Ile-Pro-Tyr, immunostimulating peptides from human milk proteins. Biochim. Biophys. Acta, 1160: 251-261.
23. Kayser, H., and Meisel, H. 1996. Stimulation of human peripheral blood lymphocytes by bioactive peptides derived from bovine milk proteins. FEBS Lett. 383: 18-20. doi:10.1016/0014-5793(96)00207-4.
24. Kimber, I., Cumberbatch, M., Dearman, R.J., Headon, D.R., Bhushan, M., and Griffiths, C.E. 2002. Lactoferrin: influences on Langerhans cells, epidermal cytokines, and cutaneous inflammation. Biochem. Cell Biol. 80: 103-107. doi:10.1139/o01-227.
25. Kormeili, T., Lowe, N.J., and Yamauchi, P.S. 2004. Psoriasis: immunopathogenesis and evolving immunomodulators and systemic therapies; U.S. experiences. Br. J. Dermatol. 151: 3-15. doi:10.1111/j.1365-2133.2004. 06009.x.
26. Lafaille, J.J. 1998. The role of helper T cell subsets in autoimmune diseases. Cytokine Growth Factor Rev. 9: 139-151. doi:10.1016/S1359- 6101(98)00009-4.
27. Langley, R.G., Krueger, G.G., and Griffiths, C.E. 2005. Psoriasis: epidemiology, clinical features, and quality of life. Ann. Rheum. Dis. 64(Suppl. 2): ii18-ii23. doi:10.1136/ard.2004.033217.
28. Lappin, M.B., and Campbell, J.D.M. 2000. The Th1-Th2 classification of cellular immune responses: concepts, current thinking and applications in haematological malignancy. Blood Rev. 14: 228-239. doi:10.1054/blre.2000. 0136.
29. Legrand, D., Elass, E., Carpentier, M., and Mazurier, J. 2006. Interactions of lactoferrin with cells involved in immune function. Biochem. Cell Biol. 84: 282-290. doi:10.1139/O06-045.
30. Linden, K.G., and Weinstein, G.D. 1999. Psoriasis: current perspectives with an emphasis on treatment. Am. J. Med. 107: 595-605. doi:10.1016/S0002-9343(99)00284-3.
31. Machnicki, M., Zimecki, M., and Zagulski, T. 1993. Lactoferrin regulates the release of tumour necrosis factor alpha and interleukin 6 in vivo. Int. J. Exp. Pathol. 74: 433-439.
32. Marshall, K. 2004. Therapeutic applications of whey protein. Altern. Med. Rev. 9: 136-156.
33. Massague, J., and Wotton, D. 2000. Transcriptional control by the TGF-beta/Smad signaling system. EMBO J. 19: 1745-1754. doi:10.1093/emboj/19.8.1745.
34. Maubois, J.-L., Fauquant, J., Jouan, P., and Bourtourault, M. 2001. Patent FR2827290.
35. Mercier, A., Gauthier, S.F., and Fliss, I. 2004. Immunomodulating effects of whey proteins and their enzymatic digests. Int. Dairy J. 14: 175-183. doi:10.1016/j.idairyj.2003.08.003.
36. Miyauchi, H., Kaino, A., Shinoda, I., Fukuwatari, Y., and Hayasawa, H. 1997. Immunomodulatory effect of bovine lactoferrin pepsin hydrolysate on murine splenocytes and Peyer's patch cells. J. Dairy Sci. 80: 2330-2339.
37. Mosmann, T.R., and Subash, S. 1996. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today, 17: 138-146. doi:10.1016/0167-5699(96)80606-2.
38. Nijsten, T., Margolis, D.J., Feldman, S.R., Rolstad, T., and Stern, R.S. 2005. Traditional systemic treatments have not fully met the needs of psoriasis patients: Results from a national survey. J. Am. Acad. Dermatol. 52: 434-444. doi:10.1016/j.jaad.2004.10.862.
39. Numerof, R.P., and Asadullah, K. 2006. Cytokine and anti-cytokine therapies for psoriasis and atopic dermatitis. BioDrugs, 20: 93-103. doi:10.2165/00063030-200620020-00004.
40. Okamoto, A., Kawamura, T., Kanbe, K., Kanamaru, Y., Ogawa, H., Okumura, K., and Nakao, A. 2005. Suppression of serum IgE response and systemic anaphylaxis in a food allergy model by orally administered high-dose TGF-beta. Int. Immunol. 17: 705-712. doi:10.1093/intimm/dxh250.
41. Penttila, I.A., Zhang, M.F., Bates, E., Regester, G., Read, L.C., and Zola, H. 2001. Immune modulation in suckling rat pups by a growth factor extract derived from milk whey. J. Dairy Res. 68: 587-599. doi:10.1017/ S0022029901005180.
42. Poulin, Y., Pouliot, Y., Lamiot, E., Aattouri, N., and Gauthier, S.F. 2005. Safety and efficacy of a milk-derived extract in the treatment of plaque psoriasis: an open-label study. J. Cutan. Med. Surg. 9: 271-275. doi:10.1007/s10227-005-0103-6.
43. Poulin, Y., Bissonnette, R., Juneau, C., Cantin, K., Drouin, R., and Poubelle, P.E. 2006. XP-828L in the treatment of mild to moderate psoriasis: randomized, double-blind, placebo-controlled study. J. Cutan. Med. Surg. 10: 241-248.
44. Soyland, E., Funk, J., Rajka, G., Sandberg, M., Thune, P., Rustad, L., et al. 1993. Effect of dietary supplementation with very-long-chain n-3 fatty acids in patients with psoriasis. N. Engl. J. Med. 328: 1812-1816. doi:10.1056/NEJM199306243282504.
45. Strober, B.E., Siu, K., and Menon, K. 2006. Conventional systemic agents for psoriasis. A systemic review. J. Rheumatol. 33: 1442-1446.
46. Veale, D.J., Torley, H.I., Richards, I.M., O'Dowd, A., Fitzsimons, C., Belch, J.J., and Sturrock, R.D. 1994. 1994. A double-blind placebo controlled trial of Efamol Marine on skin and joint symptoms of psoriatic arthritis. Br. J. Rheumatol. 33: 954-958. doi:10.1093/rheumatology/33.10.954.
47. Wahl, S.M., and Chen, W. 2005. Transforming growth factor-beta-induced regulatory T cells referee inflammatory and autoimmune diseases. Arthritis Res. Ther. 7: 62-68. doi:10.1186/ar1504.
48. Wong, C.W., Seow, H.F., Husband, A.J., Regester, G.O., and Watson, D.L. 1997. Effects of purified bovine whey factors on cellular immune functions in ruminants. Vet. Immunol. Immunopathol. 56: 85-96. doi:10.1016/S0165- 2427(96)05732-7.